163759-94-2

Basic information

• Product Name: N4-Benzoyl-5'-O-DMT-2'-O-methylcytidine 3'-CE phosphoramidite
• Synonyms: N4-Benzoyl-5'-O-DMT-2'-O-methylcytidine 3'-CE phosphoramidite;Cytidine, N-benzoyl-5'-O-[bis(4-Methoxyphenyl)phenylMethyl]-2'-O-(2-Methoxyethyl)-5-Methyl-, 3'-[2-cyanoethyl bis(1-Methylethyl)phosphoraMidite];N-Benzoyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-O-(2-methoxyethyl)-5-methylcytidine 3'-[2-cyanoethyl N,N-bis(1-methylethyl)phosphoramidite];2'-O-MOE-5Me-C(Bz)-3'-phosphoramidite;N4-Benzoyl-5'-O-(4,4'-dimethoxytrityl)-2'-O-methylcytidine-3'-(2-cyanoethyl diisopropylphosphoramidite);N4-Bz-5'-O-DMTr-2'-O-(2-methoxyethyl)-5-methylcytidine-3'-CED-phosphoramidite;N4-Benzoyl-5'-O-DMT-2'-O-(2-methoxyethyl)-5-methylcytidine 3'-CE phosphoramidite
• CAS NO: 163759-94-2
• Molecular Formula: C47H54N5O9P
• Molecular Weight: 863.933521
• Mol File: 163759-94-2.mol

Chemical Properties

• Appearance: White to Off-white/Powder
• PKA: 8.59±0.40(Predicted)
• CAS DataBase Reference: N4-Benzoyl-5'-O-DMT-2'-O-methylcytidine 3'-CE phosphoramidite(CAS DataBase Reference)
• NIST Chemistry Reference: N4-Benzoyl-5'-O-DMT-2'-O-methylcytidine 3'-CE phosphoramidite(163759-94-2)
• EPA Substance Registry System: N4-Benzoyl-5'-O-DMT-2'-O-methylcytidine 3'-CE phosphoramidite(163759-94-2)

Safety Data

• Hazardous Substances Data: 163759-94-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N4-Benzoyl-5'-O-DMT-2'-O-methylcytidine 3'-CE phosphoramidite is used as a key intermediate in the synthesis of nucleoside analogs for pharmaceutical applications. These nucleoside analogs have the potential to be developed into antiviral, anticancer, and immunosuppressive drugs due to their ability to interfere with nucleic acid synthesis and function in target cells.
Used in Chemical Research:
In the field of chemical research, N4-Benzoyl-5'-O-DMT-2'-O-methylcytidine 3'-CE phosphoramidite serves as a valuable tool for studying the structure-activity relationships of nucleoside analogs. By incorporating N4-Benzoyl-5'-O-DMT-2'-O-methylcytidine 3'-CE phosphoramidite into various nucleoside derivatives, researchers can investigate the effects of different structural modifications on the biological activity and selectivity of these compounds.
Used in Nucleic Acid Synthesis:
N4-Benzoyl-5'-O-DMT-2'-O-methylcytidine 3'-CE phosphoramidite is also used in the synthesis of modified nucleic acids, such as oligonucleotides and aptamers, for applications in molecular biology and biotechnology. These modified nucleic acids can be used as probes, primers, or inhibitors in various assays and techniques, including PCR, sequencing, and gene regulation.

Upstream product

• 182496-01-1 5'-O-(4,4'-dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-N₄-benzoyl-5-methylcytidine 
• 93183-36-9 N,N-diisopropylamine tetrazolide 
• 102691-36-1 N,N,N',N'-tetraisopropyl 2-cyanoethylphosphorodiamidite 
• 163759-50-0 5'-O-(4,4'-dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-5-methyluridine 
• 163759-49-7 2'-O-(2-methoxyethyl)-5-methyluridine 
• 40615-36-9 4,4'-dimethoxytrityl chloride 
• 292037-80-0 N⁴-benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine 
• 253156-63-7 2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine 
• 93-97-0 benzoic acid anhydride 
• 182496-00-0 2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine 
• 22423-26-3 O-2,2'-cyclo-5-methyluridine 
• 133485-25-3 bis(diisopropylamino)(2-cyanoethoxy)phosphane 

Relevant articles and documents

METHODS FOR THE PREVENTION AND TREATMENT OF MAJOR ADVERSE CARDIOVASCULAR EVENTS USING COMPOUNDS THAT MODULATE APOLIPOPROTEIN B

Provided herein, for example, are methods generally relating to preventing, treating and/or managing a major adverse cardiovascular event in a subject with a disease or condition at risk for a major adverse cardiovascular event, e.g., familial hypercholesterolemia. Also provided herein are methods relating to administering to the patient a therapeutically effective amount of an antisense oligonucleotide having a nucleobase SEQ ID NO: 247 (e.g., mipomersen).

EFFECTS OF APOLIPOPROTEIN B INHIBITION ON GENE EXPRESSION PROFILES IN ANIMALS

Antisense compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding apolipoprotein B. Methods of using these compounds for modulation of apolipoprotein B expression and for treatment of diseases associated with expression of apolipoprotein B are provided. Methods are provided for modulating the expression of genes involved in lipid metabolism, useful in the treatment of conditions associated with cardiovascular risk. Antisense oligonucleotides targeted to apolipoprotein B reduce the level of apolipoprotein B mRNA, lower serum cholesterol and shift liver gene expression profiles from those of an obese animal towards those of a lean animal. Further provided are methods for improving the cardiovascular risk of a subject through antisense inhibition of apolipoprotein B. Also provided are methods for employing antisense oligonucleotides targeted to apolipoprotein B to modulate a cellular pathway or metabolic process.

Antisense modulation of polo-like kinase expression

Antisense compounds, compositions and methods are provided for modulating the expression of polo-like kinase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding polo-like kinase. Methods of using these compounds for modulation of polo-like kinase expression and for treatment of diseases associated with expression of polo-like kinase are provided.

Antisense inhibition via RNAse H-independent reduction in mRNA

The present invention provides compositions and methods for reducing levels of a preselected mRNA, using antisense compounds targeted to a splice site or a region up to 50 nucleobases upstream of an exon/intron junction on said mRNA. Preferably, said antisense compounds do not elicit RNAse H cleavage of the mRNA.

ANTISENSE MODULATION OF STEAROYL-COA DESATURASE EXPRESSION

Antisense compounds, compositions and methods are provided for modulating the expression of stearoyl-CoA desaturase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding stearoyl-CoA desaturase. Methods of using these compounds for modulation of stearoyl-CoA desaturase expression and for treatment of diseases associated with expression of stearoyl-CoA desaturase are provided.

Modulation of CEACAM1 expression

Compounds, compositions and methods are provided for modulating the expression of CEACAM1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding CEACAM1. Methods of using these compounds for modulation of CEACAM1 expression and for diagnosis and treatment of disease associated with expression of CEACAM1 are provided.

Modulation of DC-SIGN expression

Compounds, compositions and methods are provided for modulating the expression of DC-SIGN. The compositions comprise oligonucleotides, targeted to nucleic acid encoding DC-SIGN. Methods of using these compounds for modulation of DC-SIGN expression and for diagnosis and treatment of diseases and conditions associated with expression of DC-SIGN are provided.

Antisense modulation of PPP3CB expression

Antisense compounds, compositions and methods are provided for modulating the expression of PPP3CB. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PPP3CB. Methods of using these compounds for modulation of PPP3CB expression and for treatment of diseases associated with expression of PPP3CB are provided.

Antisense modulation of perilipin expression

Antisense compounds, compositions and methods are provided for modulating the expression of perilipin. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding perilipin. Methods of using these compounds for modulation of perilipin expression and for treatment of diseases associated with expression of perilipin are provided.

Antisense modulation of EDG5 expression

Antisense compounds, compositions and methods are provided for modulating the expression of EDG5. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding EDG5. Methods of using these compounds for modulation of EDG5 expression and for treatment of diseases associated with expression of EDG5 are provided.